Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Deffered Revenue (2018 - 2023)

Historic Non-Current Deffered Revenue for RedHill Biopharma (RDHL) over the last 6 years, with Q4 2023 value amounting to $540000.0.

  • RedHill Biopharma's Non-Current Deffered Revenue fell 2800.0% to $540000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $540000.0, marking a year-over-year decrease of 2800.0%. This contributed to the annual value of $540000.0 for FY2023, which is 2800.0% down from last year.
  • As of Q4 2023, RedHill Biopharma's Non-Current Deffered Revenue stood at $540000.0, which was down 2800.0% from $750000.0 recorded in Q4 2022.
  • In the past 5 years, RedHill Biopharma's Non-Current Deffered Revenue registered a high of $750000.0 during Q4 2020, and its lowest value of $500000.0 during Q4 2019.
  • For the 5-year period, RedHill Biopharma's Non-Current Deffered Revenue averaged around $658000.0, with its median value being $750000.0 (2020).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 5000.0% in 2020, then plummeted by 2800.0% in 2023.
  • Over the past 5 years, RedHill Biopharma's Non-Current Deffered Revenue (Quarter) stood at $500000.0 in 2019, then skyrocketed by 50.0% to $750000.0 in 2020, then changed by 0.0% to $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then dropped by 28.0% to $540000.0 in 2023.
  • Its Non-Current Deffered Revenue was $540000.0 in Q4 2023, compared to $750000.0 in Q4 2022 and $750000.0 in Q4 2021.